Proxy Votes Now

Home › Funds › Equitable › EQ/AB Small Cap Growth Portfolio

EQ/AB Small Cap Growth Portfolio proxy voting record 2025-2026

Fund family: Equitable · Filed by EQ ADVISORS TRUST (CIK 1027263) · SEC series S000009056

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 725 with, 4 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 4 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Equitable as a whole

The same two figures as Equitable’s manager page (393,894 ballot items across 72 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsEquitableItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)88.5%70392.5%339,726
Backed environmental and social shareholder proposals at US companiesn/a09.6%3,486

Where this fund voted differently from most Equitable funds

Each ballot item this fund voted is set against the votes of the other Equitable funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Equitable funds on 23 items (3.4% of the 676 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Equitable fundsMgmtResult
Lumexa Imaging Holdings, Inc.2026-06-10To elect three Class I directors to the Board of Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Brian ReganForWITHHOLD — 5 of 5 Equitable fundsFor—
Dianthus Therapeutics, Inc.2026-05-21To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeWithholdFOR — 7 of 8 Equitable fundsAgainstPassed (calculated), 80.6% support
Erasca, Inc.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Alexander W. CasdinWithholdFOR — 5 of 6 Equitable fundsAgainstElected, 88.0% support
BridgeBio Pharma, Inc.2026-06-22To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly eleWithholdFOR — 5 of 8 Equitable fundsAgainstPassed (calculated), 97.3% support
BridgeBio Pharma, Inc.2026-06-22To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly eleWithholdFOR — 5 of 8 Equitable fundsAgainstPassed (calculated), 95.0% support
BridgeBio Pharma, Inc.2026-06-22To elect three (3) nominees for director, James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2028 and until their successors are duly eleWithholdFOR — 5 of 8 Equitable fundsAgainstPassed (calculated), 80.1% support
Kymera Therapeutics, Inc.2026-06-24To elect four class III directors to our Board of Directors, each to serve until the 2029 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Elena Ridloff, CFAWithholdFOR — 5 of 8 Equitable fundsAgainstPassed (calculated), 93.6% support
Granite Construction Incorporated2026-06-04Election of Directors: Carlos M. HernandezAgainstFOR — 5 of 8 Equitable fundsAgainstPassed (calculated), 96.1% support
Granite Construction Incorporated2026-06-04Election of Directors: Celeste B. MastinAgainstFOR — 5 of 8 Equitable fundsAgainstPassed (calculated), 94.6% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: David Schenkein, M.D.WithholdFOR — 5 of 8 Equitable fundsAgainstElected, 73.5% support
Nuvalent, Inc.2026-06-16Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.WithholdFOR — 5 of 8 Equitable fundsAgainstElected, 81.5% support
Generac Holdings Inc.2026-06-11Election of Class II Directors: Bennett J. MorganAgainstFOR — 8 of 15 Equitable fundsAgainstPassed (calculated), 83.3% support
Relay Therapeutics, Inc.2026-06-09To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Claire Mazumdar, Ph.D.WithholdFOR — 4 of 6 Equitable fundsAgainstElected, 83.5% support
Relay Therapeutics, Inc.2026-06-09To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Douglas S. IngramWithholdFOR — 4 of 6 Equitable fundsAgainstElected, 82.2% support
Vera Therapeutics, Inc.2026-05-21To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D.WithholdFOR — 4 of 6 Equitable fundsAgainstElected, 76.6% support
Vera Therapeutics, Inc.2026-05-21To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. EnrightWithholdFOR — 4 of 6 Equitable fundsAgainstElected, 92.5% support
Ocular Therapeutix, Inc.2026-06-10To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Merilee RainesWithholdFOR — 4 of 6 Equitable fundsAgainstElected, 86.9% support
DigitalOcean Holdings, Inc.2026-06-15Election of Class II Directors: Warren AdelmanWithholdFOR — 5 of 9 Equitable fundsAgainstPassed (calculated), 79.8% support
Guardant Health, Inc.2026-06-17Election of Class II Directors: Ian ClarkWithholdFOR — 4 of 7 Equitable fundsAgainstElected, 65.0% support
Guardant Health, Inc.2026-06-17Election of Class II Directors: Manuel Hidalgo MedinaWithholdFOR — 4 of 7 Equitable fundsAgainstElected, 75.5% support
Glaukos Corporation2026-05-28Election of Directors: Aimee S. WeisnerWithholdFOR — 4 of 7 Equitable fundsAgainstPassed (calculated), 95.0% support
Glaukos Corporation2026-05-28Election of Directors: Denice M. TorresWithholdFOR — 4 of 7 Equitable fundsAgainstPassed (calculated), 78.5% support
Edgewise Therapeutics, Inc.2026-06-04Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D.ForWITHHOLD — 3 of 5 Equitable fundsForElected, 70.3% support

Download all 23 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 85.7% of this fund’s 729 such votes could be given a sector; the other 104 (14.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care15500.0%
Industrials13521.5%
Technology11900.0%
Consumer Discretionary9911.0%
Finance5900.0%
Consumer Staples2600.0%
Energy1800.0%
Utilities10110.0%
Basic Materials400.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4840
Audit-related930
Say-on-Pay820
Compensation290
Corporate Governance234
Capital Structure190
Extraordinary Transactions50
Shareholder Rights and Defenses20
Other10
Other Social Issues10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Glaukos CorporationMay 28, 2026$29M40
Coherent Corp.November 13, 2025$28M70
Comfort Systems USA, Inc.May 18, 2026$25M120
Guardant Health, Inc.June 17, 2026$22M50
BrightSpring Health Services, Inc.May 21, 2026$21M50
Lattice Semiconductor CorporationMay 1, 2026$21M100
Bloom Energy CorporationMay 21, 2026$21M80
Rocket Lab CorporationMay 20, 2026$19M40

Notable votes against management

MeetingCompanyProposalFundMgmt
May 7, 2026Murphy USA Inc.Stockholder Proposal - Give Shareholders the Ability to Call for a Special Shareholder Meeting. Shareholder proposalForAgainst
May 11, 2026MKS Inc.A shareholder proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 10%, if properly presented at the meeting. Shareholder proposalForAgainst
May 5, 2026Albemarle CorporationShareholder Proposal regarding shareholders ability to call for a special shareholder meeting. Shareholder proposalForAgainst
May 5, 2026DT Midstream, Inc.Stockholder Proposal on Shareholder Right to Act by Written Consent. Shareholder proposalForAgainst

Search this fund’s votes by company

739 ballot items at 88 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, EQ/AB Small Cap Growth Portfolio voted at 88 shareholder meetings of 88 companies, on 739 ballot items in all. Where management made a recommendation, the fund followed it on 99.5% of the items and voted against it 4 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals less often than Equitable's funds as a whole (88.5% against 92.5%). It voted differently from most Equitable funds on 23 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Equitable’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.